Deramciclane

Drug Profile

Deramciclane

Alternative Names: Deramciclane fumarate; EGIS-3886; EGYT 3886

Latest Information Update: 26 Feb 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Orion; Pharmacia Corporation
  • Class Anxiolytics; Ethylamines; Small molecules
  • Mechanism of Action GABA uptake inhibitors; Serotonin 2A receptor antagonists; Serotonin 2C receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Generalised anxiety disorder

Most Recent Events

  • 19 Feb 2003 Discontinued - Phase-III for Generalised anxiety disorder in Europe (PO)
  • 19 Feb 2003 Discontinued - Phase-III for Generalised anxiety disorder in Finland (PO)
  • 19 Feb 2003 Discontinued - Phase-III for Generalised anxiety disorder in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top